Healthpoint Biotherapeutics

Our Story

At DFB Pharmaceuticals, we are passionate about driving practical innovations that improve healthcare outcomes. Founded in 1990, our entrepreneurial spirit has always driven us to build businesses that address unmet medical needs. With a successful track record of creating value through strategic acquisitions, product development, brand building, and operational excellence, we have realized over $1.5 billion from the growth and sale of our companies in pharmaceutical contract development and manufacturing, dermatology, and wound care.

Our Business Model

Our business model is built on a foundation of collaboration, innovation, and flexibility. We partner with corporate partners, academic institutions, clinical experts, and other investor groups to identify, invest in, and develop new products and businesses that solve critical unmet healthcare needs. With a strong focus on entrepreneurship, we are able to remain agile and responsive to changing market conditions and emerging opportunities.

Our Companies

Over the years, we have built a diverse portfolio of companies, each focused on addressing specific healthcare challenges. These companies have achieved significant success, and we have realized substantial returns on our investments. Some of our notable companies include:

NanOlogy LLC

NanOlogy is a clinical-stage oncology company that is advancing a patented particle engineering technology designed for intratumoral delivery, aiming to improve the treatment of solid tumors.

Phyton Biotech

Phyton Biotech is a comprehensive provider of high-quality Paclitaxel and Docetaxel API via plant cell fermentation (PCF) technology. We acquired Phyton in 2003 and have since expanded its capabilities to include the development of plant-derived pharmaceuticals.

DFB Technology

DFB Technology is a commercial healthcare product distributor globally.

Our History

Our story began in 1990 when our founder, H. Paul Dorman, and his partners acquired Dermatological Products of Texas (DPT) from Alcon Laboratories. Since then, we have established a track record of success, growing our companies and generating significant returns on our investments. We have achieved milestones such as pioneering the use of pharmaceuticals in wound care, establishing a dermatology company, and developing and commercializing a portfolio of surgical antisepsis technologies.

Our Leadership

Our Chairman and CEO, H. Paul Dorman, has been instrumental in shaping our company's vision and guiding our growth. With over three decades of entrepreneurial experience, Paul has led DFB Pharmaceuticals to achieve significant success and has built a strong foundation for future growth.

Our Commitment

At DFB Pharmaceuticals, we are committed to driving practical innovations that improve healthcare outcomes. We believe that by partnering with like-minded individuals and organizations, we can make a lasting impact on the lives of patients around the world.